A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

NCT01732198 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Infectious Disease

Interventions

BIOLOGICAL: NU300
BIOLOGICAL: ActHIB
BIOLOGICAL: Prevnar 13

Sponsor

Nuron Biotech Inc.